Vancouver, Wash.-based CytoDyn Inc. raised approximately $9.9 million via the sale of 19,823,260 units at 50 cents apiece.
Each unit was made up of a common share and a warrant to purchase an additional stock at 75 cents each.
CytoDyn is developing treatments for HIV.